Morphic to Present at TD Cowen 43rd Annual Health Care Conference
Morphic Therapeutic (Nasdaq: MORF) announced its participation in the TD Cowen 43rd Annual Health Care Conference, focusing on innovative treatments for gastroenterological diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Morphic Therapeutic (Nasdaq: MORF) announced its participation in the TD Cowen 43rd Annual Health Care Conference, focusing on innovative treatments for gastroenterological diseases. The management team will engage in a GI/Microbiome Panel Discussion at 9:10 AM ET and a Fireside Chat at 11:10 AM ET on March 6, 2023. A live webcast will be accessible on the Investor section of Morphic's website, with an archived replay available afterward. Morphic is dedicated to developing oral integrin therapies for serious chronic diseases, supported by its proprietary MInT technology platform and collaborations with Janssen.
Details
News Market Reaction – MORF
The recorded move for MORF in the trading session of this news was +1.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference.
Presentation Information
GI/Microbiome Panel Discussion
9:10 AM ET, Monday March 6, 2023
Fireside Chat
11:10 AM ET, Monday, March 6, 2023
A live webcast of the presentations will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaborations with Janssen using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.